Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more
Market Cap & Net Worth: Actinogen Medical Limited (ATGGF)
Actinogen Medical Limited (PINK:ATGGF) has a market capitalization of $86.55 Million ($86.55 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #20162 globally and #7340 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Actinogen Medical Limited's stock price $0.03 by its total outstanding shares 3461912195 (3.46 Billion).
Actinogen Medical Limited Market Cap History: 2018 to 2025
Actinogen Medical Limited's market capitalization history from 2018 to 2025. Data shows change from $173.10 Million to $86.55 Million (-10.32% CAGR).
Actinogen Medical Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Actinogen Medical Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
15.77x
Actinogen Medical Limited's market cap is 15.77 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $173.10 Million | $3.30 Million | -$6.23 Million | 52.44x | N/A |
| 2019 | $100.40 Million | $4.86 Million | -$9.89 Million | 20.65x | N/A |
| 2020 | $83.09 Million | $3.52 Million | -$5.33 Million | 23.63x | N/A |
| 2021 | $83.09 Million | $1.98 Million | -$3.92 Million | 41.88x | N/A |
| 2022 | $346.19 Million | $3.64 Million | -$9.50 Million | 95.11x | N/A |
| 2023 | $51.93 Million | $4.89 Million | -$10.75 Million | 10.62x | N/A |
| 2024 | $69.24 Million | $9.93 Million | -$13.04 Million | 6.97x | N/A |
| 2025 | $86.55 Million | $5.49 Million | -$14.73 Million | 15.77x | N/A |
Competitor Companies of ATGGF by Market Capitalization
Companies near Actinogen Medical Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Actinogen Medical Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Actinogen Medical Limited Historical Marketcap From 2018 to 2025
Between 2018 and today, Actinogen Medical Limited's market cap moved from $173.10 Million to $ 86.55 Million, with a yearly change of -10.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $86.55 Million | +25.00% |
| 2024 | $69.24 Million | +33.33% |
| 2023 | $51.93 Million | -85.00% |
| 2022 | $346.19 Million | +316.67% |
| 2021 | $83.09 Million | 0.00% |
| 2020 | $83.09 Million | -17.24% |
| 2019 | $100.40 Million | -42.00% |
| 2018 | $173.10 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Actinogen Medical Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $86.55 Million USD |
| MoneyControl | $86.55 Million USD |
| MarketWatch | $86.55 Million USD |
| marketcap.company | $86.55 Million USD |
| Reuters | $86.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.